TiGenix: Corporate Presentation (TiGenix) - Apr 23, 2015 - “Favorable safety profile of all three doses of Cx611”; “Only on patient experienced a serious adverse event leading to discontinuation of the treatment, All other side effects were mild and transient: most common related adverse events in the Cx611+DMARD group: fever (15%), headache (9%), asthenia (6%)”; “Encouraging therapeutic activity”
P1/2 data • Rheumatoid Arthritis
|